Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 mg daily dose compared to placebo.
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
By Josiah Agoro We are aware of a trending video in which distinguished Senator Ned Nwoko, representing Delta North Senatorial zone in the National Assembly, during a courtesy visit to the Ndokwa Neku ...
Josema Giménez found the net with a looping header in the 90th minute, and Atlético Madrid completed a comeback from 1-0 down ...
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...
Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.
Boom Supersonic announces its supersonic demonstrator aircraft, XB-1, has successfully completed its third flight using digitally-optimized aerodynamics, carbon fiber composites and advanced ...
The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...
In the second virtual workshop of the summer, El Dorado County’s team for the Tahoe El Dorado Area Plan presented the feedback and engagement received over the summer ...
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
BNZ has secured a €166 million (US$185.4 million) loan from the European Investment Bank (EIB) for 700MW of new solar ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback